
Post-COVID-19, India needs to strengthen its pharma R&D ecosystem to tap into emerging drug development opportunities, particularly in the realm of infectious diseases. As the global R&D ecosystem moves towards a more collaborative approach and possibly accelerated new drug development cycles, India needs to reorient its pharma industry to become...









